SEL24/MEN1703 for Leukemia, Myeloid

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
ASST Monza - Ospedale San Gerardo, Monza, Italy
Leukemia, Myeloid+3 More
SEL24/MEN1703 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug may help treat acute myeloid leukemia.

See full description

Eligible Conditions

  • Leukemia, Myeloid
  • Acute Myeloid Leukemia (AML)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Leukemia, Myeloid

Study Objectives

This trial is evaluating whether SEL24/MEN1703 will improve 1 primary outcome and 1 secondary outcome in patients with Leukemia, Myeloid. Measurement will happen over the course of DLTs in patients during their first 21-day treatment cycle.

DLTs in patients during their first 21-day treatment cycle
Dose limiting toxicity (DLT) evaluation
Day 30
Safety profile of single agent SEL24/MEN1703

Trial Safety

Safety Progress

1 of 3

Other trials for Leukemia, Myeloid

Trial Design

1 Treatment Group

SEL24/MEN1703
1 of 1
Experimental Treatment

This trial requires 68 total participants across 1 different treatment group

This trial involves a single treatment. SEL24/MEN1703 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

SEL24/MEN1703
Drug
SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle. Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients. Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from cycle 1 day 1 to final study visit (up to 30 days after last administered dose). each cycle lasts 21 days.
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly from cycle 1 day 1 to final study visit (up to 30 days after last administered dose). each cycle lasts 21 days. for reporting.

Closest Location

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Leukemia, Myeloid or one of the other 3 conditions listed above. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Patients with Acute Myeloid Leukemia who have been diagnosed with an IDH1 or IDH2 mutation are being recruited for this study. show original
The patient has relapsed AML that is unsuitable for intensive chemotherapy and ineligible for any approved targeted therapy show original

Patient Q&A Section

What are the signs of leukemia, myeloid, acute?

"An enlarged liver and an enlarged spleen are common, but leukemic cells do not usually accumulate in the spleen or liver. Most patients have bone loss. Atypical features of myelogenous leukemia include hepatosplenomegaly, pancytosis, and blast hyperplasia. Atypical features of acute lymphoblastic leukemia include lymphadenopathy, splenomegaly, and splenic infiltration. Atypical features of acute myelogenous leukemia include anemia, thrombocytopenia, leukopenia, and hyperbasophilia." - Anonymous Online Contributor

Unverified Answer

What are common treatments for leukemia, myeloid, acute?

"Patients were treated mainly with corticosteroids, inducible antithreonoglobulin, and chemotherapy for acute leukemia. Newer drugs such as proteasome inhibitors and imatinib were used to treat chronic lymphocytic leukemia and chronic myeloid and acute myeloid leukemia." - Anonymous Online Contributor

Unverified Answer

What is leukemia, myeloid, acute?

"Acute myeloid leukemia accounts for approximately one-third of all new leukemias diagnosed annually in Japan. The majority of the patients have low or normal levels of white cell count and no abnormalities in hematopoietic progenitors. The high-risk group of AML with more than 20% blasts may receive a high risk of prognosis and/or chemotherapeutic treatment should be indicated for them." - Anonymous Online Contributor

Unverified Answer

Can leukemia, myeloid, acute be cured?

"Can leukemias, myeloid, acute be cured? answer: It is possible in some instances to achieve a complete remission of disease and long-term survival. The optimal timing and methods for obtaining these results are undefined." - Anonymous Online Contributor

Unverified Answer

How many people get leukemia, myeloid, acute a year in the United States?

"In 1999, approximately 30000 new cases of leukemias and neutropenias and 3500 cases of CLL, AL, AML, and HL were diagnosed in the United States. AML occurred at a rate that was similar to but much higher than that for most of the other leukemias and HL. In contrast to Western nations, there continues to be important racial differences in the American incidence of leukemia, myeloid, acute." - Anonymous Online Contributor

Unverified Answer

What causes leukemia, myeloid, acute?

"Leukemia, myeloid/acute, is caused by abnormal development in the formation of blood cell precursors in the bone marrow. It is usually caused by one of two mechanisms, hematopoietic stem cell (HSC) mutations or abnormal signaling. In both instances, exposure to ionizing radiation or to chemotherapy can cause leukemia or myeloid/acute. Lymphoma, leukemic, is caused by a malignancy of B cells or T cells. It can be acquired or de novo and is related to a variety of health problems. Myeloma, myeloid/lymphoid, is caused by the clonal recruitment of malignant light chains into bone marrow." - Anonymous Online Contributor

Unverified Answer

What are the chances of developing leukemia, myeloid, acute?

"In case of acute leukemia, a person's overall survival is usually good with aggressive treatments (Bone Marrow Transplantation, Bone Marrow Transplant HCT [Hematopoietic Cell Transplantation], or HCT BMT) being common. But some of these treatments have significant side effects. A recent study estimated that the chance of developing leukemia, myeloid, acute in the future is about 4.2% after five years. With this number, it is important to be aware before participating in a clinical trial, so that you know some of the treatment options. If you want to join a clinical trial, [withpower.com](https://www.power." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for leukemia, myeloid, acute?

"To conduct additional prospective studies or clinical trials, patients should not exclude themselves purely based on their age or the presence of comorbidities (such as lung disease, alcoholism, or diabetes), but take into special account individual risks associated with both treatment and the risks of the disease itself. We should ensure that we know which treatment will be effective for whom; we must therefore be aware of the possibility of bias, due to a choice between a treatment and a patient based on a number of factors." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of leukemia, myeloid, acute?

"There are several common events that lead to the development of leukemia, myeloid, acute, which are not exclusive to this disease. To improve survivability, patients requiring chemotherapy should be managed as a whole to address a patient's primary etiology." - Anonymous Online Contributor

Unverified Answer

Does leukemia, myeloid, acute run in families?

"Data from a recent study showed a higher rate of MAF amongst families with a history of AML, highlighting the importance of further research into its genetic, familial clustering, and environmental aetiology." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for leukemia, myeloid, acute?

"Results from a recent paper supports the idea that patients with AML, MCL, and ALL at their acute stage have a better survival rate compared with patients who have their leukemia in chronic stage. Moreover, AML patients who present with a normal and stable neutrophil count have a significantly longer survival rate compared with patients of chronic AML. The prognostic factors for survival are, in order of significance, gender (male), age, time from disease diagnosis (diagnosed <3 yr ago), and age at AML diagnosis (<61 yr)." - Anonymous Online Contributor

Unverified Answer

Is sel24/men1703 safe for people?

"The data suggest that Sel24/Meneh1703 is well tolerated in men with castration resistant prostate cancer. Longer-term study is now required to confirm these results and investigate the potential for this treatment to be effective for people with castration resistant prostate cancer." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Leukemia, Myeloid by sharing your contact details with the study coordinator.